维思通与奎硫平治疗精神分裂症阴性症状对照分析  

The cross-check analysis of risperdal and quetiapine alleviating negative symptoms of schizophrenia

作　　者：李登明[1] 

机构地区：[1]四川省攀枝花市第三人民医院,617061

出　　处：《检验医学与临床》2008年第19期1162-1163,共2页Laboratory Medicine and Clinic

摘　　要：目的探讨维思通与奎硫平治疗精神分裂症阴性症状的疗效及不良反应。方法采用随机对照研究方法,用维思通和奎硫平分别治疗以阴性症状为主的精神分裂症。疗程12周,以精神病评定量表、阴性症状表评定疗效,以不良反应量表评定药物不良反应。结果两种药物对精神分裂症阴性症状疗效近似。维思通对意志缺乏、兴趣缺乏及社交缺乏等症状改善明显,不良反应少且轻微;奎硫平对认知功能缺失、情感症状改善明显,锥体外系症状发生率低。结论维思通与奎硫平治疗精神分裂症阴性症状均有效,且疗效相当,不良反应发生率低。Objective To investigate the efficacy and adverse reactions of risperdal and quetiapine alleviating negative symptoms of schizophrenia. Methods Randomized controlled trial was performed to study the efficacy and adverse reactions of risperdal and quetiapine alleviating negative symptoms of schizophrenia. The course of treatment was 12 weeks. Brief Psychiatric Reacting Stale （BPRS） and Scale for the Assessment of Negative Symptoms （SANS） were applied to assessing the therapeutic effect, and Treatment Emergent Symptom Scale （TESS） applied to assessing the adverse reaction. Results The therapeutic effect of risperdal and quetiapine were approximate to the schizophrenia negative symptom. Risperdal markedly ameliorated the symptoms of abulia, lack of interest and social intercourse, which adverse effects were slight and fewer; while quetiapine greatly improved the symptoms of cognition function loss and affective disturbance, which prevalence of extrapyramidal symptoms was low. Conclusion Risperdal and quetiapine are both effective to amelioration of negative symptoms of schizophrenia. Their therapeutic effect is equivalent, and adverse effects are fewer.

关 键 词：维思通 奎硫平 精神分裂症 阴性症状 

分 类 号：R749.3[医药卫生—神经病学与精神病学]